Tactile Systems Technology, Inc. (TCMD) Análise de ações

Visão geral da empresa

A medical technology enterprise, Tactile Systems Technology, Inc. focuses on developing and supplying specialized medical devices designed to treat underserved chronic conditions within the United States healthcare landscape. The company operates within the Healthcare sector, specifically targeting the Medical Devices industry, where innovation in therapeutic equipment is critical for patient outcomes. Its operational scale is represented by a market capitalization of $549.19M, an annual revenue of $329.52M, and a workforce comprising 1086 employees. These financial metrics indicate a mid-cap position that has achieved significant revenue generation relative to its market valuation, suggesting a stable yet growing presence in the specialized medical device market. The disparity between its substantial revenue base and its market cap implies a valuation that may reflect specific market sentiment regarding its growth trajectory or competitive positioning within the niche of chronic disease management.

Saúde financeira

The company reported a trailing twelve-month revenue of $329.52M and generated a net income of $19.09M, while EBITDA reached $35.92M. The significant gap between the revenue figure and the net income reveals a cost structure where operating expenses and taxes consume approximately 74.1% of total revenue before considering the EBITDA buffer. Free cash flow stands at $34.58M, indicating a robust ability to generate cash from operations after capital expenditures, which provides the firm with substantial financial flexibility for strategic investments or debt reduction. Analysis of the three key margins shows a Gross Margin of 75.9%, an Operating Margin of 18.1%, and a Profit Margin of 5.8%; the high gross margin reflects strong pricing power or cost efficiencies in production, while the lower operating and profit margins suggest significant investment in selling, general, and administrative expenses relative to sales. The company holds $83.45M in cash against $15.96M in debt, resulting in a debt-to-equity ratio of 7.29, which indicates a conservative balance sheet structure with minimal leverage exposure despite the ratio's mathematical appearance. A Current Ratio of 4.03 demonstrates excellent short-term liquidity, meaning the company possesses more than four times the current assets necessary to cover its current liabilities without needing external financing. Furthermore, Return on Equity is 8.8% and Return on Assets is 6.4%, metrics that reveal the efficiency of management in generating returns from shareholders' capital and the total asset base, respectively, within the context of a capital-intensive medical device industry.

Avaliação de valorização

The trailing P/E ratio is 29.44, while the forward P/E is 16.31; the substantial difference between these two figures implies that the market expects earnings to grow significantly in the coming year, driving the valuation multiple down from the historical average. The Price to Book ratio is 2.47, indicating that the market values the company at a premium of roughly 147% over its book value, which is typical for technology firms but requires scrutiny regarding asset quality. Alternative valuation metrics such as the Price to Sales ratio of 1.67 and an EV/EBITDA of 13.20 suggest that the stock is priced relative to its sales volume and enterprise value efficiency rather than just earnings, providing a broader perspective on valuation that accounts for non-operating assets and interest obligations. The 52-week high is $37.77 and the 52-week low is $8.61; without a specific current price provided in the data, the range establishes a volatility envelope where the stock has demonstrated resilience by trading well above its lowest point of $8.61. The Beta value of 0.99 indicates that the stock's price volatility is roughly in line with the broader market, suggesting it does not exhibit extreme sensitivity to market-wide fluctuations compared to high-beta or low-beta peers.

Growth & Income

Revenue growth stands at 21.0% year over year, while earnings growth is recorded at 17.6%; earnings are growing at a slightly slower pace than revenue, which implies that cost of goods sold or operating expenses are increasing at a rate that keeps pace with or exceeds revenue expansion. As the company does not currently pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, it prioritizes retaining earnings to fuel internal growth initiatives, research and development, and capital allocation strategies rather than distributing income to shareholders. This reinvestment approach aligns with the capital-intensive nature of the medical device sector, where significant cash reserves are often required for manufacturing and regulatory compliance. The overall growth and income profile characterizes Tactile Systems Technology as a growth-oriented entity that forgoes current income distribution to capitalize on market opportunities and expand its product portfolio in the chronic disease treatment space.